StrataMGT in the Reduction of Vulvar Lichen Sclerosus (LS) Symptoms

Last updated: November 7, 2024
Sponsor: Andrew T. Goldstein, MD
Overall Status: Active - Recruiting

Phase

1

Condition

N/A

Treatment

StrataMGT

Placebo

Clinical Study ID

NCT06662942
CVVD005
24-02-237
  • Ages > 18
  • Female

Study Summary

This study is designed to evaluate the efficacy and safety of StrataMGT for the management of vulvar lichen sclerosus symptoms.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Female, 18 years or older.

  • With a diagnosis of biopsy proven vulvar lichen sclerosus.

  • Signed written informed consent.

  • Willingness and ability to comply with the study requirements.

  • Subject must have a score of 10 or greater in the VQLI at screening.

  • Must be on a stable regimen of topical corticosteroids or topical calcineurininhibitor for at least 2 months prior to the screening visit.

  • Women currently on a stable regimen of intravaginal estrogen therapy for at least 2months may remain on the estrogen therapy throughout the study.

  • Women currently using topical estrogen therapy on the vulva must stop two weeksprior to enrolling in the study.

  • Women must have a culture negative for candidiasis or bacterial vaginosis atscreening.

Exclusion

Exclusion Criteria:

  • Who are immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich Syndrome) or havean uncontrolled malignant disease.

  • Who suffer from a topical or systemic infections (bacterial, viral or fungal) at thetime of screening. Subjects who screen positive for either candidiasis or bacterialvaginosis at the screening visit may be treated and retested and may participate ifthe confirmatory test after treatment is negative. Any vulvovaginal infectionsduring their participation in the study will be considered an adverse event. Thesubject will then stop the study IP and will be treated for the infection and mayresume use of the IP 3 days after the last dose of medication for the infection.They will be discontinued from the study if they have two infections during thestudy.

  • Who have been diagnosed with lichen planus, psoriasis, intraepithelial neoplasia, orcarcinoma of the vulva.

  • Who had received an investigational drug within four weeks prior to the study or whointend to use other investigational drugs during the course of this study.

  • Patients with severe medical condition(s) that in the view of the investigatorprohibits participation in the study.

  • Who have a history of substance abuse or any factor, which limits the subject'sability to cooperate with the study procedures.

  • Who are uncooperative, known to miss appointments (according to subjects' records)and are unlikely to follow medical instructions or are not willing to attendregularly scheduled visits.

Study Design

Total Participants: 100
Treatment Group(s): 2
Primary Treatment: StrataMGT
Phase: 1
Study Start date:
October 16, 2024
Estimated Completion Date:
October 16, 2025

Study Description

This will be a randomized double-blind placebo-controlled trial to evaluate the efficacy and safety of StrataMGT for the management of the symptoms of vulvar lichen sclerosus. Up to 100 patients with a diagnosis of biopsy proven vulvar lichen sclerosus will be recruited from two centers. This study will consist of a two-week screening period and a 12-week treatment period. At the beginning of the screening period, a vulvoscopy will be performed at the screening visit and after the 12-week treatment period to rule out vulvar intrepithelial neoplasia (VIN) or carcinoma. All eligible patients will be randomized to receive either placebo gel or treatments with the investigation product, StrataMGT TM 1:1 ratio.

The primary efficacy endpoint will be change in score on the Vulvar Quality of Life Index 11 (VQLI).

Secondary efficacy endpoints will be the Skindex 29, and the Clinical Lichen Sclerosus Scoring Scale (CLISSCO).

All adverse events will be recorded, including serious adverse events. A physical examination will be performed at each visit.

Connect with a study center

  • Centers for Vulvovaginal Disorders, DC

    Washington, District of Columbia 20037
    United States

    Active - Recruiting

  • Centers for Vulvovaginal Disorders, FL

    Tampa, Florida 33609
    United States

    Active - Recruiting

  • Centers for Vulvovaginal Disorders, NY

    New York, New York 10036
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.